ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1145

Roxadustat in Treating Anemia in Dialysis Patients (ROAD): Short-Term Impact on Serum Triglyceride

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Hong, Daqing, Department of Nephrology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
  • Xue, Hen, Department of Nephrology, Ya'an People's Hospital, Chengdu, China
  • Cai, Yanrong, Gao Xin Boli Hospital, Chengdu, China
  • He, Jingdong, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China
  • He, Qiang, Department of Nephrology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
  • Li, Guisen, Department of Nephrology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Background

Roxadustat has been shown effective in lowering serum cholesterol in treating patients with anemia due to chronic kidney disease. However, its effect on serum triglyceride (TG), especially in dialysis patients that have high prevalence of hypertriglyceridemia remains unknow. This analysis is to provide clinical data of Roxadustat on serum TG in a real-world prospective observational cohort.

Methods

This is a multicenter, prospective, longitudinal observational cohort study assessing if Roxadustat improves prognosis in at least 250 dialysis patients with renal anemia. Primary outcomes will be major cardiovascular events. The current analysis was done in the enrolled 144 patients to compare the changes of serum TG from baseline to current follow up. The analysis was done in the whole cohort and subgroups according to baseline serum TG level.

Results

Till May 20, 2020. 144 dialysis participants (76 male, mean age 52+/-15 years) were enrolled from 11 sites of the study with a follow up of 8 (0~12) weeks. The primary disease of kidney failure was predominantly primary glomerulonephritis (67 cases, 46.5 %) and diabetes (28 cases, 19.4%). The serum TG at baseline and at the last follow up was 2.06+/-1.58 mmol/L (range from 0.14 to 12.04 mmol/L) and 1.90+/-1.09mmol/L respectively (p=0.162). In patients with TG greater than 1.7mmol/L, serum TG decreased significantly (n=53, 2.59+/-1.06 vs. 3.09+/-1.75 mmol/L, p=0.028) after Roxadustat treatment with -0.50mmol/L (95%CI: -0.05, 0.95mmol/L).

Conclusion

Hypertriglyceridemia is prevalent in ROAD cohort. Roxadustat could alter serum TG, especially lowering its level in dialysis anemia patients with hypertriglyceridemia which should be confirmed in future studies.

TG changes from ROAD cohort.